International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

J Eur Acad Dermatol Venereol. 2023 Dec 6. doi: 10.1111/jdv.19681. Online ahead of print.

Christos C Zouboulis^{1

2}, Errol P Prens^{1

3}, Christopher J Sayed^{1

4}, Alejandro Molina-Leyva^{1

5}, Vincenzo Bettoli^{1

6}, Marco Romanelli^{1

7}, Jacek C Szepietowski^{1

8}, Angela Llobet Martinez⁹, Torben Kasparek⁹, Iryna Lobach⁹, Magdalena B Wozniak¹⁰, Christine-Elke Ortmann⁹, Nicolas Thomas⁹, Teresa Bachhuber⁹, Shoba Ravichandran¹¹, Thrasyvoulos Tzellos^{1

12}

¹ European Hidradenitis Suppurativa Foundation (EHSF), Dessau, Germany.
² Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
³ Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
⁴ Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁵ Hidradenitis Suppurativa Unit, Instituto de Investigación Biosanitaria ibs and Servicio de Dermatologia, Hospital Universitario Virgen de Las Nieves, Granada, Spain.
⁶ Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
⁷ Department of Dermatology, University of Pisa, Pisa, Italy.
⁸ Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland.
⁹ Novartis Pharma AG, Basel, Switzerland.
¹⁰ Novartis Ireland Limited, Dublin, Ireland.
¹¹ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
¹² Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.

No abstract available

Publication types